Drugs / NG11-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06669390 | May 2023 → Aug 2024 | mucositis | VasoDynamics Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NG11-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06669390 ↗ |
| Route | Oral | “The NG11-2 is given as an oral rinse.” NCT06669390 ↗ |